Moleculin reports 43% complete remission rate in Annamycin arm of Phase 2/3 AML trial
Bitget2026/11/04 16:01- Moleculin Biotech will present interim Annamycin trial results at the ASH annual meeting in New Orleans, Dec. 12-15, 2026.
- The pivotal Phase 2/3 study found higher complete remission rates with Annamycin plus cytarabine than placebo in relapsed or refractory acute myeloid leukemia.
- No signs of cardiotoxicity were observed through the data cutoff; independent cardiac safety reviews are planned at the second interim analysis.
- An independent monitoring committee recommended continuing the trial without changes, retaining all three treatment arms.
- The second interim analysis is expected in early 2027; a successful trial could support a New Drug Application submission.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
